• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.

作者信息

Pardanani A, Abdelrahman R A, Finke C, Lasho T T, Begna K H, Al-Kali A, Hogan W J, Litzow M R, Hanson C A, Ketterling R P, Tefferi A

机构信息

Division of Hematology and Department of Medicine, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.

Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.

出版信息

Leukemia. 2015 Mar;29(3):741-4. doi: 10.1038/leu.2014.306. Epub 2014 Nov 11.

DOI:10.1038/leu.2014.306
PMID:25322686
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4360208/
Abstract
摘要

相似文献

1
Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.莫洛替尼治疗的骨髓纤维化患者反应和生存的遗传决定因素。
Leukemia. 2015 Mar;29(3):741-4. doi: 10.1038/leu.2014.306. Epub 2014 Nov 11.
2
Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.原发性血小板增多症和原发性骨髓纤维化的突变状态决定临床结局。
Haematologica. 2016 Apr;101(4):e129-32. doi: 10.3324/haematol.2015.138958. Epub 2016 Jan 14.
3
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.芦可替尼治疗的骨髓纤维化患者中突变谱与反应的相关性
Blood. 2015 Aug 6;126(6):790-7. doi: 10.1182/blood-2015-03-633404. Epub 2015 Jun 29.
4
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.一种由年龄、JAK2、CALR和MPL突变状态组成的用于原发性骨髓纤维化患者的准确、简单的预后模型。
Haematologica. 2017 Jan;102(1):79-84. doi: 10.3324/haematol.2016.149765. Epub 2016 Sep 29.
5
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.JAK1和JAK2抑制剂莫洛替尼治疗骨髓纤维化的长期疗效和安全性
Leukemia. 2018 Apr;32(4):1035-1038. doi: 10.1038/leu.2017.330. Epub 2017 Nov 16.
6
How many JAK inhibitors in myelofibrosis?骨髓纤维化中有多少种JAK抑制剂？
Best Pract Res Clin Haematol. 2014 Jun;27(2):187-95. doi: 10.1016/j.beha.2014.07.010. Epub 2014 Jul 18.
7
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant.骨髓纤维化中Calr 1型/类突变是莫洛替尼药物生存期及非移植情况下长期生存的最显著预测指标。
Blood Cancer J. 2024 Mar 19;14(1):51. doi: 10.1038/s41408-024-01028-4.
8
Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis.骨髓纤维化分级是原发性骨髓纤维化患者总生存期的独立危险因素。
Blood Cancer J. 2016 Dec 9;6(12):e505. doi: 10.1038/bcj.2016.116.
9
Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis.原发性和继发性骨髓纤维化之间，驱动基因突变特异性的临床和基因组相关性存在差异。
Am J Hematol. 2019 Dec;94(12):E314-E317. doi: 10.1002/ajh.25625. Epub 2019 Sep 10.
10
Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.莫洛替尼治疗骨髓纤维化：一种在治疗和理解贫血方面具有作用的JAK1/2抑制剂。
Future Oncol. 2017 Feb;13(5):395-407. doi: 10.2217/fon-2016-0417. Epub 2016 Oct 27.

引用本文的文献

1
Advances in Stem Cell Transplantation for Myelofibrosis.骨髓纤维化的干细胞移植进展。
Curr Hematol Malig Rep. 2024 Dec;19(6):256-263. doi: 10.1007/s11899-024-00742-x. Epub 2024 Sep 6.
2
Momelotinib for the treatment of myelofibrosis.莫雷洛替尼治疗骨髓纤维化。
Blood. 2024 Aug 15;144(7):708-713. doi: 10.1182/blood.2023023719.
3
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval.Momelotinib用于治疗骨髓纤维化：我们对100例临床试验患者的14年经验及美国食品药品监督管理局近期的批准。

本文引用的文献

1
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.JAK1和JAK2抑制剂莫洛替尼治疗骨髓纤维化的长期疗效和安全性
Leukemia. 2018 Apr;32(4):1035-1038. doi: 10.1038/leu.2017.330. Epub 2017 Nov 16.
2
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.分子注释的原发性血小板增多症、真性红细胞增多症和骨髓纤维化的长期生存及原始细胞转化
Blood. 2014 Oct 16;124(16):2507-13; quiz 2615. doi: 10.1182/blood-2014-05-579136. Epub 2014 Jul 18.
3
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
Blood Cancer J. 2024 Mar 18;14(1):47. doi: 10.1038/s41408-024-01029-3.
4
Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.莫米松（JAK1/JAK2/ACVR1 抑制剂）：作用机制、临床试验报告以及除骨髓纤维化之外的治疗前景。
Haematologica. 2023 Nov 1;108(11):2919-2932. doi: 10.3324/haematol.2022.282612.
5
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor.生存决定因素和对接受莫米松尼布、鲁索替尼、菲特那替尼或 BMS-911543 JAK2 抑制剂治疗的 183 例骨髓纤维化临床试验患者的回顾性比较。
Blood Cancer J. 2023 Jan 4;13(1):3. doi: 10.1038/s41408-022-00780-9.
6
Mutant Calreticulin in the Myeloproliferative Neoplasms.骨髓增殖性肿瘤中的突变型钙网蛋白
Hemasphere. 2020 Jan 15;4(1):e333. doi: 10.1097/HS9.0000000000000333. eCollection 2020 Feb.
7
Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN.Ph 阴性骨髓增殖性肿瘤的非 JAK-STAT 治疗新靶点
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):407-414. doi: 10.1182/hematology.2019000048.
8
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.HDAC11 缺失破坏骨髓增殖性肿瘤中癌基因诱导的造血。
Blood. 2020 Jan 16;135(3):191-207. doi: 10.1182/blood.2019895326.
9
Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience.二代测序在骨髓增殖性肿瘤管理中的临床应用：单中心经验
Hemasphere. 2018 May 4;2(3):e44. doi: 10.1097/HS9.0000000000000044. eCollection 2018 Jun.
10
Targeted therapies for myeloproliferative neoplasms.骨髓增殖性肿瘤的靶向治疗
Biomark Res. 2019 Jul 16;7:15. doi: 10.1186/s40364-019-0166-y. eCollection 2019.
原发性骨髓纤维化中预后不良突变的数量和预后：一项对 797 例患者的国际研究。
Leukemia. 2014 Sep;28(9):1804-10. doi: 10.1038/leu.2014.76. Epub 2014 Feb 19.
4
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.CALR 和 ASXL1 基因突变在原发性骨髓纤维化中的分子预后：一项 570 例患者的国际研究。
Leukemia. 2014 Jul;28(7):1494-500. doi: 10.1038/leu.2014.57. Epub 2014 Feb 5.
5
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.在 COMFORT-II 研究中，接受芦可替尼治疗的骨髓纤维化患者中突变状态对结局的影响。
Blood. 2014 Apr 3;123(14):2157-60. doi: 10.1182/blood-2013-11-536557. Epub 2014 Jan 23.
6
Mutations and prognosis in primary myelofibrosis.原发性骨髓纤维化中的突变与预后。
Leukemia. 2013 Sep;27(9):1861-9. doi: 10.1038/leu.2013.119. Epub 2013 Apr 26.
7
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.CYT387，一种 JAK1 和 JAK2 抑制剂，在骨髓纤维化中的安全性和疗效。
Leukemia. 2013 Jun;27(6):1322-7. doi: 10.1038/leu.2013.71. Epub 2013 Mar 5.
8
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.世界卫生组织（WHO）髓系肿瘤和急性白血病分类的2008年修订版：基本原理及重要变化
Blood. 2009 Jul 30;114(5):937-51. doi: 10.1182/blood-2009-03-209262. Epub 2009 Apr 8.
9
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).国际工作组（IWG）关于骨髓化生伴骨髓纤维化治疗反应的共识标准，适用于骨髓纤维化研究与治疗国际工作组（IWG-MRT）。
Blood. 2006 Sep 1;108(5):1497-503. doi: 10.1182/blood-2006-03-009746. Epub 2006 May 4.